Regression of metastatic, radiation/chemotherapy-resistant uterine serous carcinoma overexpressing HER2/neu with trastuzumab emtansine (TDM-1)

Regression of metastatic, radiation/chemotherapy-resistant uterine serous carcinoma overexpressing HER2/neu with trastuzumab emtansine (TDM-1)

Background: The management of uterine-serous-carcinoma (USC) no longer amenable to treatment with surgery, radiation and/or chemotherapy remains dismal. Alternative therapeutic options are desperately needed. Case: We describe the case of a heavily pretreated 74-year-old patient with a recurrent USC...

Full description

Bibliographic Details
Main Authors:	Alessandro D. Santin, Stefania Bellone, Natalia Buza, Peter E. Schwartz
Format:	Article
Language:	English
Published:	Elsevier 2017-02-01
Series:	Gynecologic Oncology Reports
Subjects:	Uterine serous carcinoma Trastuzumab-emtansine HER2/neu
Online Access:	http://www.sciencedirect.com/science/article/pii/S2352578916300881

Similar Items

Selection of HER2/NEU negative tumor cells as a mechanism of resistance to trastuzumab in uterine serous carcinoma
by: Silvia Pelligra, et al.
Published: (2020-05-01)

Trastuzumab deruxtecan in recurrent uterine serous carcinoma resistant to trastuzmab based-chemotherapy
by: Blair McNamara, et al.
Published: (2023-08-01)

Safety and efficacy of trastuzumab emtansine (TDM-1) in a patient on hemodialysis for renal failure
by: A. Falcón González, et al.
Published: (2021-01-01)

Second-Line Treatment of HER2-Positive Salivary Gland Tumor: Ado-Trastuzumab Emtansine (T-DM1) after Progression on Trastuzumab
by: Tatiana Strava Corrêa, et al.
Published: (2018-05-01)

Trastuzumab emtansine of the treatment of HER2-positive breast cancer with brain metatases
by: L. Yu. Vladimirova, et al.
Published: (2020-12-01)

Neu Perspectives, Therapies, and Challenges for Metastatic HER2-Positive Breast Cancer
by: Salkeni MA, et al.
Published: (2021-09-01)

Cost-effectiveness analysis of trastuzumab deruxtecan versus trastuzumab emtansine for HER2-positive breast cancer
by: Jiangping Yang, et al.
Published: (2022-09-01)

Cancer-derived exosomes from HER2-positive cancer cells carry trastuzumab-emtansine into cancer cells leading to growth inhibition and caspase activation
by: Mark Barok, et al.
Published: (2018-05-01)

The role of autophagy in the cytotoxicity induced by trastuzumab emtansine (T-DM1) in HER2-positive breast cancer cells
by: Peipei Liu, et al.
Published: (2020-06-01)

Novel approaches to target HER2-positive breast cancer: trastuzumab emtansine
by: Recondo G Jr, et al.
Published: (2016-05-01)

Cost-effectiveness analysis of Ado-trastuzumab emtansine for the treatment of residual invasive HER2-positive breast cancer
by: Marcos Aurélio Fonseca Magalhães Filho, et al.
Published: (2022-05-01)

Tumor biomarkers and efficacy in patients treated with trastuzumab emtansine + pertuzumab versus standard of care in HER2-positive early breast cancer: an open-label, phase III study (KRISTINE)
by: Sanne L. de Haas, et al.
Published: (2023-01-01)

Trastuzumab Emtansine (T-DM1) and stereotactic radiation in the management of HER2+ breast cancer brain metastases
by: Matthew N. Mills, et al.
Published: (2021-03-01)

Efficacy and safety of trastuzumab emtansine treatment in patients with metastatic HER-2 positive breast cancer: a single center study
by: Eyyup Cavdar, et al.
Published: (2022-08-01)

Impacts of clinicopathological factors on efficacy of trastuzumab deruxtecan in patients with HER2-positive metastatic breast cancer
by: Hiromichi Nakajima, et al.
Published: (2022-02-01)

Trastuzumab emtansine vs lapatinib and capecitabine in HER2-positive metastatic breast cancer brain metastases: A real-world study
by: Thibaut Sanglier, et al.
Published: (2023-06-01)

Trastuzumab deruxtecan versus trastuzumab emtansine for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: A cost-effectiveness analysis
by: Youwen Zhu, et al.
Published: (2022-12-01)

Trastuzumab Emtansine for the Treatment of HER-2 Positive Carcinoma Ex-pleomorphic Adenoma Metastatic to the Brain: A Case Report
by: Ihab Hassanieh, et al.
Published: (2018-07-01)

Role of Post-Neoadjuvant therapy with trastuzumab emtansine in HER2-positive breast cancer
by: E. V. Lubennikova, et al.
Published: (2021-12-01)

Trastuzumab Emtansine Plus Non-Pegylated Liposomal Doxorubicin in HER2-Positive Metastatic Breast Cancer (Thelma): A Single-Arm, Multicenter, Phase Ib Trial
by: Elena López-Miranda, et al.
Published: (2020-11-01)

Developments in the Management of Metastatic HER2-Positive Breast Cancer: A Review
by: Julie Lebert, et al.
Published: (2022-04-01)

Human epidermal growth factor receptor 2 (Her2) testing for uterine serous carcinoma: Report of scenarios of unusual overexpression
by: M. Ruhul Quddus, et al.
Published: (2020-05-01)

Ado-Trastuzumab Emtansine-Induced Pulmonary Toxicity: A Single-Institution Retrospective Review
by: Heidi Egloff, et al.
Published: (2018-08-01)

Whether HER2-positive non-breast cancers are candidates for treatment with Ado-trastuzumab emtansine?
by: Azadeh Moghaddas, et al.
Published: (2016-01-01)

TRASTUZUMAB BEYOND PROGRESSION IN PATIENTS WITH HER-2/NEU POSITIVE METASTATIC BREAST CANCER
by: Yeşim Eralp
Published: (2009-01-01)

Anti-HER2/neu Antibody Reduces Chemotherapy-Induced Ovarian Toxicity—From Bench to Bedside
by: Mattan Levi, et al.
Published: (2020-12-01)

Lacrimal drainage system stenosis associated with Trastuzumab emtansine (Kadcyla®, T-DM1) administration: a case report
by: Chung Young Kim, et al.
Published: (2019-08-01)

Progression-Free Survival and Overall Survival in Patients with Advanced HER2-Positive Breast Cancer Treated with Trastuzumab Emtansine (T-DM1) after Previous Treatment with Pertuzumab
by: Laura L. Michel, et al.
Published: (2020-10-01)

Improving Receptor-Mediated Intracellular Access and Accumulation of Antibody Therapeutics—The Tale of HER2
by: Jeffrey V. Leyton
Published: (2020-07-01)

Dose-Reduced Trastuzumab Emtansine: Active and Safe in Acute Hepatic Dysfunction
by: Adam Sharp, et al.
Published: (2015-02-01)

Aggressive HER2-Positive Gastric Cancer in a Young Patient, Refractory in Trastuzumab and Progressive with Trastuzumab-Emtansine Treatment
by: Vildana Goga Çmega, et al.
Published: (2024-03-01)

cERBB-2/Her-2 Neu Overexpression and Prognostic Significance in Uterine Carcinosarcoma
by: Huseyin Salih SEMIZ, et al.
Published: (2023-01-01)

Change in HER-2/neu Status from Negative to Positive following Treatment in Breast Cancer: A Case Report
by: Lakshmi Sivarajan, et al.
Published: (2011-01-01)

T-DM1 efficacy in trastuzumab-pertuzumab pre-treated HER2 positive metastatic breast cancer patients: a meta-analysis
by: Claudia Omarini, et al.
Published: (2022-06-01)

HER-2/neu overexpression in breast cancer
by: Rana S. Aziz, et al.
Published: (2010-10-01)

Real-world effectiveness of post-trastuzumab emtansine treatment in patients with HER2-positive, unresectable and/or metastatic breast cancer: a retrospective observational study (KBCSG-TR 1917)
by: Takahiro Nakayama, et al.
Published: (2021-07-01)

Real world data on the demographic and clinicopathological profile and management of patients with early-stage HER2-positive breast cancer and residual disease treated with adjuvant trastuzumab emtansine (KARMA study)
by: Silvia Antolín Novoa, et al.
Published: (2023-01-01)

T-DM1 after Pertuzumab plus Trastuzumab: Treatment Sequence-Induced Selection Bias in HER2-Positive Metastatic Breast Cancer
by: Thibaut Sanglier, et al.
Published: (2022-05-01)

Implementation of Systematic Bioanalysis of Antibody–Drug Conjugates for Preclinical Pharmacokinetic Study of Ado-Trastuzumab Emtansine (T-DM1) in Rats
by: Eun-Jeong Jeon, et al.
Published: (2023-02-01)

Expression of Her2-Neu in Primary Gastric and Gastroesophageal Adenocarcinoma: An Experience from a Tertiary Center in South India
by: Aditi Damle, et al.